Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

CDKN3 Antikörper (N-Term)

Der Kaninchen Polyklonal Anti-CDKN3-Antikörper wurde für WB validiert. Er ist geeignet, CDKN3 in Proben von Human zu detektieren. Es sind 5+ Publikationen verfügbar.
Produktnummer ABIN1881194

Kurzübersicht für CDKN3 Antikörper (N-Term) (ABIN1881194)

Target

Alle CDKN3 Antikörper anzeigen
CDKN3 (Cyclin-Dependent Kinase Inhibitor 3 (CDKN3))

Reaktivität

  • 69
  • 23
  • 13
  • 4
  • 4
  • 3
  • 3
  • 2
  • 2
  • 2
Human

Wirt

  • 62
  • 7
Kaninchen

Klonalität

  • 64
  • 5
Polyklonal

Konjugat

  • 29
  • 6
  • 6
  • 5
  • 3
  • 3
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
Dieser CDKN3 Antikörper ist unkonjugiert

Applikation

  • 56
  • 31
  • 18
  • 13
  • 13
  • 7
  • 6
  • 5
  • 5
  • 3
  • 3
  • 1
  • 1
Western Blotting (WB)

Klon

RB42328
  • Bindungsspezifität

    • 15
    • 8
    • 8
    • 6
    • 6
    • 3
    • 3
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 39-68, N-Term

    Aufreinigung

    This antibody is purified through a protein A column, followed by peptide affinity purification.

    Immunogen

    This CDKN3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 39-68 amino acids from the N-terminal region of human CDKN3.

    Isotyp

    Ig Fraction
  • Applikationshinweise

    WB: 1:1000

    Beschränkungen

    Nur für Forschungszwecke einsetzbar
  • Format

    Liquid

    Buffer

    Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

    Konservierungsmittel

    Sodium azide

    Vorsichtsmaßnahmen

    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Lagerung

    4 °C,-20 °C

    Haltbarkeit

    6 months
  • Jiang, Xia, Li, Deng, Zhao, Shi, Wang, Sun: "High expression levels of IKKalpha and IKKbeta are necessary for the malignant properties of liver cancer." in: International journal of cancer. Journal international du cancer, Vol. 126, Issue 5, pp. 1263-74, (2010) (PubMed).

    Shimada, Miyagawa, Kawashima, Tanaka, Honda, Honda, Tokunaga: "An approach based on a genome-wide association study reveals candidate loci for narcolepsy." in: Human genetics, Vol. 128, Issue 4, pp. 433-41, (2010) (PubMed).

    Okamoto, Kitabayashi, Taya: "KAP1 dictates p53 response induced by chemotherapeutic agents via Mdm2 interaction." in: Biochemical and biophysical research communications, Vol. 351, Issue 1, pp. 216-22, (2006) (PubMed).

    Hsieh, Yao, Lai, Yang: "Transcriptional repression activity of PAX3 is modulated by competition between corepressor KAP1 and heterochromatin protein 1." in: Biochemical and biophysical research communications, Vol. 349, Issue 2, pp. 573-81, (2006) (PubMed).

    Chinami, Yano, Yang, Salahuddin, Moriyama, Shiroishi, Turner, Shirakawa, Adra et al.: "Binding of HTm4 to cyclin-dependent kinase (Cdk)-associated phosphatase (KAP).Cdk2.cyclin A complex enhances the phosphatase activity of KAP, dissociates cyclin A, and facilitates KAP..." in: The Journal of biological chemistry, Vol. 280, Issue 17, pp. 17235-42, (2005) (PubMed).

  • Target

    CDKN3 (Cyclin-Dependent Kinase Inhibitor 3 (CDKN3))

    Andere Bezeichnung

    CDKN3

    Hintergrund

    The protein encoded by this gene belongs to the dual specificity protein phosphatase family. It was identified as a cyclin-dependent kinase inhibitor, and has been shown to interact with, and dephosphorylate CDK2 kinase, thus prevent the activation of CDK2 kinase. This gene was reported to be deleted, mutated, or overexpressed in several kinds of cancers. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.

    Molekulargewicht

    23805

    NCBI Accession

    NP_001124323, NP_005183

    UniProt

    Q16667
Sie sind hier:
Chat with us!